key: cord-1049101-us5o3zvu
authors: Di Vincenzo, A.; Andrisani, A.; Vettor, R.; Rossato, M.
title: Estrogen and COVID-19: friend or foe?
date: 2021-03-29
journal: Ann Oncol
DOI: 10.1016/j.annonc.2021.03.201
sha: e8bd0c2ba1aa8c45609dbed398a4fa35d0fc5727
doc_id: 1049101
cord_uid: us5o3zvu

nan

We have read the paper by Montopoli et al. reporting the possible COVID-19 protective role of anti-estrogenic therapy in women treated for breast and ovarian cancer. 1 Since the SARS-CoV-2 infection outbreak in December 2019, it has been shown that the majority of patients hospitalized for COVID-19 are males. 2 These observations, confirmed worldwide, defined a clear sex difference associated with COVID-19 morbidity and mortality. 2 In particular, the prevalence of premenopausal women among COVID-19 patients is very low, 3 

Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy

Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis

Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection

Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice

Evidence for treatment with estradiol for women with SARS-CoV-2 infection